{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:18:59Z","timestamp":1778872739575,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinthera.2021.09.019","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T01:52:06Z","timestamp":1636595526000},"page":"2013-2023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Changying","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-2440","authenticated-orcid":false,"given":"Guiling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hellawell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-3068","authenticated-orcid":false,"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.09.019_bib0001","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2014.08.023","article-title":"Peritoneal dialysis in China: Meeting the challenge of chronic kidney failure","volume":"65","author":"Yu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0003","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1097\/01.ASN.0000034202.91413.EB","article-title":"The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease","volume":"13","author":"De Boer","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/184321","article-title":"International burden of chronic kidney disease and secondary hyperparathyroidism: A systematic review of the literature and available data","volume":"2015","author":"Hedgeman","year":"2015","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Dr\u00fceke","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0006","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0008","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0009","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0010","unstructured":"Cinacalcet (Mimpara\u00ae), Amgen Inc.,Thousand Oaks, CA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mimpara-epar-product-information_en.pdf 2021"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0011","unstructured":"Cinacalcet (Sensipar\u00ae), Amgen Inc.,Thousand Oaks, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021688s023lbl.pdf 2021"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0012","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/hdi.12410","article-title":"Efficacy and safety of cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis","volume":"20","author":"Mei","year":"2016","journal-title":"Hemodial Int"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0013","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ekir.2017.01.016","article-title":"A single- and multiple-dose, multicenter study of etelcalcetide in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"2","author":"Yokoyama","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0014","unstructured":"Etelcalcetide (Parsabiv\u00ae), SmPC, Amgen Inc.,Thousand Oaks, CA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/parsabiv-epar-product-information_en.pdf 2021"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0015","unstructured":"Etelcalcetide (Parsabiv\u00ae), Prescribing Information, Amgen Inc.,Thousand Oaks, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208325Orig1s000Lbledt.pdf 2021"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0016","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0017","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12882-017-0665-8","article-title":"Hemodialysis patients' preferences for the management of secondary hyperparathyroidism","volume":"18","author":"Hauber","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/104892","article-title":"Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study","volume":"2013","author":"Forni Ogna","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0019","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","article-title":"A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"31","author":"Bell","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jcph.1090","article-title":"Clinical pharmacokinetics and pharmacodynamics of etelcalcetide, a novel calcimimetic for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","volume":"58","author":"Wu","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0021","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/psp4.12106","article-title":"Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis","volume":"5","author":"Chen","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2017.03.005","article-title":"Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments","volume":"445","author":"Kroenke","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0024","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","article-title":"One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism","volume":"35","author":"Bushinsky","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2021.09.019_bib0025","unstructured":"Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian HD Subjects With SHPT. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03299244. 2021"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:30Z","timestamp":1758963330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821003921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0149291821003921"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}